{"id":"NCT00880100","sponsor":"Forest Laboratories","briefTitle":"Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)","officialTitle":"Efficacy and Safety of Ultrase MT12 in the Control of Steatorrhea in Cystic Fibrosis (CF) and Pancreatic Insufficient (PI) Children Aged 2 to 6 Years Old","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2009-04-13","resultsPosted":"2015-02-19","lastUpdate":"2017-03-16"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis","Pancreatic Insufficiency"],"interventions":[{"type":"DRUG","name":"Ultrase® MT12","otherNames":[]}],"arms":[{"label":"Ultrase® MT12","type":"EXPERIMENTAL"}],"summary":"Multicenter, explorative, phase IIIb, open-label study to assess the efficacy and safety of Ultrase® MT12, in the control of steatorrhea and clinical signs and symptoms of malabsorption in CF children with pancreatic insufficiency (PI). This study is sponsored by Aptalis Pharma (formerly Axcan).","primaryOutcome":{"measure":"Percentage of Patients With Control of Steatorrhea","timeFrame":"A period of 19 to 24 days, from Baseline (Visit 2) to Day 15 to19 of Treatment Phase (Visit 3)","effectByArm":[{"arm":"Ultrase® MT12","deltaMin":46.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":17},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Cough","Vomiting","Pyrexia","Nasal congestion","Constipation"]}}